Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

13 Oct 2014

Anaphylaxis Campaign to hold special event to help prevent food business errors

The Anaphylaxis Campaign is set to hold a special event for the food industry on Tuesday 7th October 2014 to help prevent food business errors reaching crisis point.

30 Sep 2014

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences Corporation, manufacturer of the revolutionary Flublok influenza vaccine, announced today that doses of the vaccine have been released and are now available for shipment.

29 Sep 2014

Dry roasted peanuts more likely to trigger allergy risk

Dry roasted peanuts are more likely to trigger an allergy to peanuts than raw peanuts, suggests an Oxford University study involving mice.

22 Sep 2014

Researchers aim to safely and quickly suppress food allergies in human

In mice, the answer appears to be "yes," but making sure the same can happen in humans is a task that Fred Finkelman, MD, professor of medicine and pediatrics in the University of Cincinnati's (UC) College of Medicine and a researcher at Cincinnati Children's Hospital Medical Center, is attempting to tackle.

9 Sep 2014

FDA approves use of Menactra for booster vaccination against meningococcal disease

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.

9 Sep 2014

People with food allergies have to watch what their fruits and vegetables eat

People with food allergies always have to watch what they eat. Now, they may have to watch what their fruits and vegetables eat, as it seems it's possible to have an allergic reaction to antibiotic residues in food.

4 Sep 2014

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.

From Baxter International Inc. 22 Aug 2014

New method could make cashews safer for people with allergies

For the millions of adults and children in the U.S. who have to shun nuts to avoid an allergic reaction, help could be on the way. Scientists are now developing a method to process cashews - and potentially other nuts - that could make them safer to eat for people who are allergic to them.

11 Aug 2014

Tips from ACAAI to help kids enjoy healthy, symptom-free days in classroom

Your kids may be enjoying the lazy days of summer, but if they have asthma, allergies, or both, they need to be prepared for back-to-school. And so do their classrooms. More than 10 million kids under age 18 have asthma, and 11 percent suffer from respiratory allergies. About 6 percent have also been diagnosed with food allergies.

1 Aug 2014

GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to U.S. healthcare providers. This is the first shipment of GSK’s U.S. flu vaccine supply for the flu season, following licensing and lot-release approval from the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research.

17 Jul 2014

Allergy & Asthma Network, ALAA to increase awareness on life-threatening latex allergies

Allergy & Asthma Network, a leading nonprofit patient education organization, is pleased to announce that its Anaphylaxis Community Expert (ACE) volunteer program is partnering with the American Latex Allergy Association (ALAA) to increase awareness about life-threatening latex allergies.

10 Jul 2014

FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

Protein Sciences Corporation announced today that the FDA has approved the Company's strain change amendment for its seasonal influenza vaccine, Flublok.

9 Jul 2014

Tips to help kids enjoy healthy, symptom-free days in classroom and on sports field

Your kids may be enjoying the lazy days of summer, but if they have asthma, allergies - or both - they need to be prepared for back-to-school. And so do their classrooms. More than 10 million kids under age 18 have asthma, and 11 percent suffer from respiratory allergies. About 6 percent have also been diagnosed with food allergies.

17 Jun 2014

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza.

31 May 2014

GE Healthcare to supply technetium-99m generators following FDA approval

Effective from June 1st 2014 and following approval by the US Food and Drug Administration (FDA), GE Healthcare today announced the intent to supply generators for the production of sodium pertechnetate; technetium (Tc99m) injection to its radiopharmacies in the US.

31 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones.

19 May 2014

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

A new subcutaneous formulation of RoActemra® (tocilizumab) has today been launched providing thousands of UK rheumatoid arthritis (RA) patients with a potentially life-changing treatment option.1